Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status
Authors:
- Phuong MaiPMPhuong Mai
- Nora K. HorickNHNora K. Horick
- Marion PiedmonteMPMarion Piedmonte
- Charles W. DrescherCDCharles W. Drescher
- Claudine IsaacsCIClaudine Isaacs
- Deborah K. ArmstrongDADeborah K. Armstrong
- Saundra S. BuysSBSaundra S. Buys
- Gustavo C. RodriguezGRGustavo C. Rodriguez
- Ira R. HorowitzIHIra R. Horowitz
- Andrew BerchuckABAndrew Berchuck
- Mary B. DalyMDMary B. Daly
- 1 September 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 4 (9) , 1401-1408
Abstract
Previous screening trials for early detection of ovarian cancer in postmenopausal women have used the standard CA125 cut-point of 35 U/mL, the 98th percentile in this population yielding a 2% false positive rate, whereas the same cut-point in trials of premenopausal women results in substantially higher false positive rates. We investigated demographic and clinical factors predicting CA125 distributions, including 98th percentiles, in a large population of high-risk women participating in two ovarian cancer screening studies with common eligibility criteria and screening protocols. Baseline CA125 values and clinical and demographic data from 3,692 women participating in screening studies conducted by the National Cancer Institute–sponsored Cancer Genetics Network and Gynecologic Oncology Group were combined for this preplanned analysis. Because of the large effect of menopausal status on CA125 levels, statistical analyses were conducted separately in pre- and postmenopausal subjects to determine the impact of other baseline factors on predicted CA125 cut-points on the basis of 98th percentile. The primary clinical factor affecting CA125 cut-points was menopausal status, with premenopausal women having a significantly higher cut-point of 50 U/mL, while in postmenopausal subjects the standard cut-point of 35 U/mL was recapitulated. In premenopausal women, current oral contraceptive (OC) users had a cut-point of 40 U/mL. To achieve a 2% false positive rate in ovarian cancer screening trials and in high-risk women choosing to be screened, the cut-point for initial CA125 testing should be personalized primarily for menopausal status (50 for premenopausal women, 40 for premenopausal on OC, and 35 for postmenopausal women). Cancer Prev Res; 4(9); 1401–8. ©2011 AACR.Keywords
This publication has 18 references indexed in Scilit:
- A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian CancerCancer Prevention Research, 2011
- A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group StudyCancer Epidemiology, Biomarkers & Prevention, 2008
- Ovarian cancer death reduction for women at high risk: Workload implications for gynaecology servicesJournal of Obstetrics and Gynaecology, 2006
- Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trialAmerican Journal of Obstetrics and Gynecology, 2005
- Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of lifeGynecologic Oncology, 2003
- Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2MutationNew England Journal of Medicine, 2002
- Prospectively detected cancer in familial breast/ovarian cancer screeningActa Obstetricia et Gynecologica Scandinavica, 1999
- Screening for ovarian cancer: a pilot randomised controlled trialThe Lancet, 1999
- New reference levels for CA125 in pre- and postmenopausal womenPrimary Care Update for OB/GYNS, 1998
- The CA 125 tumour-associated antigen: a review of the literatureHuman Reproduction, 1989